上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02607 上海医药

午间休市 08-07 12:05:00

11.810

+0.010

+0.08%

最高11.830	最低11.730	成交量37.69万
今开11.800	昨收11.800	日振幅0.85%
总市值437.91亿	流通市值108.54亿	总股本37.08亿
成交额443.76万	换手率0.04%	流通股本9.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.81,"timestamp":1786075500006,"preClose":11.8,"halted":0,"volume":376900,"delay":0,"changeRate":0.0008474576271186259,"floatShares":919072704,"shares":3708000000,"eps":1.539999,"marketStatus":"午间休市","change":0.01,"latestTime":"08-07 12:05:00","open":11.8,"high":11.83,"low":11.73,"amount":4437631,"amplitude":0.008475,"askPrice":11.82,"askSize":700,"bidPrice":11.81,"bidSize":6200,"shortable":3,"etf":0,"ttmEps":1.776382,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786078800000},"marketStatusCode":3,"adr":0,"listingDate":1305820800000,"exchange":"SEHK","adjPreClose":11.8,"dividendRate":0.045877,"openAndCloseTimeList":[[1786066200000,1786075200000],[1786078800000,1786089600000]],"volumeRatio":0.671962,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.49,"timestamp":1786073398000,"preClose":16.43,"halted":0,"volume":6386800,"delay":0,"premium":"-38.41"}},"requestUrl":"/m/hq/s/02607","defaultTab":"news","newsList":[{"id":"2657565215","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657565215","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657565215?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:08","pubTimestamp":1785870494,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属上药信谊药厂奥美拉唑碳酸氢钠干混悬剂获国家药监局批准生产，已投入研发费用约593.55万元，2025年该药品中国大陆医院采购金额为1,569万元。公司公告汇总上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂获得批准生产的公告上海医药下属上海上药信谊药厂有限公司收到国家药品监督管理局颁发的《药品注册证书》，奥美拉唑碳酸氢钠干混悬剂获批生产。该药品用于活动性十二指肠溃疡和胃食管反流病的短期治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1197","BK0099","BK0020","02607","BK0184","BK0175","BK0188","BK0028","BK0097","BK0196","601607","BK0012","BK0187","BK0209","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539305","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539305","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656539305?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:29","pubTimestamp":1785778149,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属上药信谊药厂奥美拉唑碳酸氢钠干混悬剂获国家药监局批准生产，已投入研发费用约593.55万元，2025年该药品中国大陆医院采购金额为1,569万元。公司公告汇总上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂获得批准生产的公告上海医药集团股份有限公司下属上海上药信谊药厂有限公司收到国家药品监督管理局颁发的《药品注册证书》，奥美拉唑碳酸氢钠干混悬剂获得批准生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK1197","BK0175","BK0183","BK0188","BK0012","BK0099","BK0097","02607","601607","BK0184","BK0028","BK0020","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100013670","title":"上海医药（02607）旗下上药信谊获批生产奥美拉唑碳酸氢钠干混悬剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1100013670","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100013670?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:36","pubTimestamp":1785753383,"startTime":"0","endTime":"0","summary":"2026年8月4日，上海医药集团股份有限公司公告称，其全资子公司上海上药信谊药厂有限公司已收到国家药品监督管理局签发的《药品注册证书》，奥美拉唑碳酸氢钠干混悬剂获准生产。该药品为口服混悬剂，每袋含奥美拉唑20mg及碳酸氢钠1,680mg，按照化学药品3类注册，获得“国药准字H20265385”。奥美拉唑碳酸氢钠干混悬剂主要用于活动性十二指肠溃疡的短期治疗和胃食管反流病，原研药由Salix Pharmaceuticals Inc开发，商品名为Zegerid，于2004年6月在美国获批上市。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154361808","title":"上海医药7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1154361808","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154361808?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:41","pubTimestamp":1785750083,"startTime":"0","endTime":"0","summary":"上海医药集团股份有限公司于2026年8月3日发布截至2026年7月31日的股份变动月报表。报告期为2026年7月，本月无新增发行、购回、注销及库藏股变化。截至2026年7月底，公司股本总数维持平稳，符合香港联交所相关公众持股量的要求。上海医药集团股份有限公司同时确认，报告期内所有证券发行或库藏股份转让事宜均依据相关法律法规与香港联交所《上市规则》办理，并经董事会正式批准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656132424","title":"上海医药最新公告：奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2656132424","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656132424?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:50","pubTimestamp":1785747032,"startTime":"0","endTime":"0","summary":"上海医药(601607.SH)公告称，公司下属上药信谊收到国家药监局颁发的关于奥美拉唑碳酸氢钠干混悬剂(I)的《药品注册证书》，该药品获得批准生产。该药品主要用于活动性十二指肠溃疡的短期治疗和胃食管反流病。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300021820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0099","BK0183","BK0187","BK1197","02607","BK0028","BK0209","601607","BK0188","BK0097","BK0020","BK0196","BK0184","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656319656","title":"每周股票复盘：上海医药（601607）瑞舒伐他汀依折麦布片获准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2656319656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656319656?lang=zh_cn&edition=full","pubTime":"2026-08-02 03:15","pubTimestamp":1785611713,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，上海医药报收于16.86元，较上周的16.38元上涨2.93%。本周，上海医药7月31日盘中最高价报16.86元。公司公告汇总上海医药集团股份有限公司下属常州制药厂有限公司收到国家药监局颁发的瑞舒伐他汀依折麦布片（Ⅰ）《药品注册证书》，该药品获得批准生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0097","BK0187","BK0196","BK0209","02607","BK0028","BK0020","BK0188","BK1197","BK0184","601607","BK0099","BK0183","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391506","title":"上海医药“存贷双高”：账上躺着327亿 短期借款仍高达440亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391506","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656391506?lang=zh_cn&edition=full","pubTime":"2026-08-01 04:28","pubTimestamp":1785529707,"startTime":"0","endTime":"0","summary":"“存贷双高的问题算是监管正式提出了。”近日，上海医药（601607.SH、2607.HK）披露2025年年报信息监管问询函回复，有投资者在平台上如此说道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608013828791364.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608013828791364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601607","BK0209","BK1197","02607","BK0099","BK0020","BK0183","BK0012","BK0184","BK0028","BK0097","BK0175","BK0196","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196175338","title":"上海医药两项产品境内外获批　拓展心血管与OTC海外市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1196175338","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196175338?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:36","pubTimestamp":1785407760,"startTime":"0","endTime":"0","summary":"2026年7月31日，上海医药集团股份有限公司发布海外监管公告称，旗下两款重点产品近期分别取得中国国家药监局生产批件及加拿大卫生部产品许可证。上海医药下属常州制药厂有限公司已收到国家药品监督管理局签发的《药品注册证书》。上海医药表示，瑞舒伐他汀依折麦布片（Ⅰ）按新注册分类获批，有望在医保支付和医疗机构采购中获得支持；龙虎系列产品取得加拿大许可证，将帮助公司拓展海外OTC市场。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655782971","title":"上海医药(601607.SH)：瑞舒伐他汀依折麦布片(Ⅰ)获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2655782971","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655782971?lang=zh_cn&edition=full","pubTime":"2026-07-30 15:59","pubTimestamp":1785398348,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)收到国家药品监督管理局颁发的关于瑞舒伐他汀依折麦布片(Ⅰ)的《药品注册证书》(证书编号：2026S02581)，该药品获得批准生产。瑞舒伐他汀依折麦布片适用于高胆固醇血症或纯合子型家族性高胆固醇血症(HoFH)，由Sanofi-aventis,S.R.O.公司开发，2014年07月在欧盟上市，商品名为Zenon Neo。2024年12月，常州制药厂有限公司就该药品向国家药监局提出注册上市申请，并获受理。截至公告日，公司针对该药品已投入研发费用约人民币968万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","601607","BK0187","BK0099","BK0188","BK0020","02607","BK0097","BK1197","BK0012","BK0175","BK0184","BK0209","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655882925","title":"上海医药(601607.SH)：龙虎清凉油经典款等三款产品获加拿大产品许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2655882925","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655882925?lang=zh_cn&edition=full","pubTime":"2026-07-30 15:57","pubTimestamp":1785398232,"startTime":"0","endTime":"0","summary":"龙虎清凉油经典款、龙虎清凉油强效款、龙虎滚珠风油精这三款产品主要适用于暂时缓解肌肉和关节的酸痛/不适。2026年5月，上药中华向加拿大卫生部天然与非处方健康产品管理局递交产品注册申请。截至本公告日，公司针对前述产品在加拿大上市已投入注册费用约人民币4.95万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","02607","BK0188","BK0175","BK0184","BK0012","BK0099","BK1197","BK0209","BK0028","BK0097","BK0020","BK0183","BK0196","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655890582","title":"股市必读：上海医药（601607）7月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655890582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655890582?lang=zh_cn&edition=full","pubTime":"2026-07-30 01:35","pubTimestamp":1785346511,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘，上海医药报收于16.6元，上涨0.91%，换手率0.45%，成交量12.57万手，成交额2.09亿元。董秘最新回复投资者： 尊敬的董秘，您好！2026年《财富》世界500强企业最新发布，公司是否位列排行之中？2025年公司营业收入2,835.80亿元人民币，同比增长3.03%；实现归属于上市公司股东的净利润57.25亿元人民币，同比上升25.74%。当日关注点交易信息汇总：7月29日上海医药主力资金净流入363.7万元，游资资金净流出1609.35万元，散户资金净流入1245.65万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000000862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0184","BK0012","BK0183","BK0097","BK0187","02607","BK0020","601607","BK0188","BK0099","BK0209","BK0028","BK0175","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655611860","title":"上海医药：2026年第一季度公司药品CSO业务新承接7个品种的商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2655611860","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655611860?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:00","pubTimestamp":1785326400,"startTime":"0","endTime":"0","summary":"证券日报网7月29日讯，上海医药在接受调研时表示，2026年第一季度，公司药品CSO业务，新承接7个品种的商业化合作，产品矩阵持续优化丰富，为后续业绩增长奠定了扎实基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607293825276947.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607293825276947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601607","BK0097","BK0187","BK0188","BK0209","BK0184","BK0028","BK0196","BK0012","BK0020","BK0099","BK0175","02607","BK1197","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655860648","title":"上海医药：公司收购上海和黄后，双方整合大品种开发、循证医学研究、中药国际化等核心资源","url":"https://stock-news.laohu8.com/highlight/detail?id=2655860648","media":"证券日报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655860648?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:58","pubTimestamp":1785326280,"startTime":"0","endTime":"0","summary":"证券日报网7月29日讯，上海医药在接受调研时表示，公司收购上海和黄后，双方依托彼此在产业链和渠道网络等方面的资源优势，整合大品种开发、循证医学研究、中药国际化等核心资源，赋能集团中药业务高质量发展。一方面，公司将借鉴融合上海和黄在中药大品种创新改良方面的丰富经验与管理体系，利用循证医学等手段，加快培育胃复春、八宝丹、冠心宁等系列名优中药品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607293825275880.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607293825275880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0184","BK0028","BK0183","BK0196","BK0097","BK0209","02607","BK0175","BK0099","BK0188","BK1197","BK0187","BK0020","601607","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654020804","title":"上海医药、君实生物等成立新私募基金 出资额15亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2654020804","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654020804?lang=zh_cn&edition=full","pubTime":"2026-07-28 11:18","pubTimestamp":1785208680,"startTime":"0","endTime":"0","summary":"【上海医药、君实生物等成立新私募基金 出资额15亿】天眼查App显示，近日，上海上实生物医药产业私募基金合伙企业（有限合伙）成立，执行事务合伙人为上海上实资本管理有限公司、上海上实生物医药管理咨询有限公司，出资额15亿人民币，经营范围为以私募基金从事股权投资、投资管理、资产管理等活动。合伙人信息显示，该基金由上海国投先导生物医药私募投资基金合伙企业（有限合伙）、上海医药集团股份有限公司、上海君实生物医药科技股份有限公司等共同出资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823297587.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823297587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","BK1583","BK0188","BK0012","601607","BK0099","BK0196","BK1515","BK0187","02607","BK0097","BK1161","BK0020","BK0184","BK0028","01877","BK0209","BK0175","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654176095","title":"上海医药2025年三大业务板块毛利率集体下滑遭问询 公司回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2654176095","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654176095?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:13","pubTimestamp":1785118380,"startTime":"0","endTime":"0","summary":"南方财经7月27日电，上交所近日就上海医药(601607.SH)2025年年报下发监管问询函，重点关注公司主营业务三大板块毛利率集体下滑。问询函要求公司补充披露工业、分销、零售板块的产品结构、集采影响及同行业对比情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607273821800044.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607273821800044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0187","02607","BK0183","BK1197","BK0028","601607","BK0099","BK0196","BK0012","BK0188","BK0020","BK0184","BK0097","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052272","title":"每周股票复盘：上海医药（601607）终止丹酚酸A临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052272?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:50","pubTimestamp":1785001823,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，上海医药报收于16.38元，较上周的16.61元下跌1.38%。本周，上海医药7月21日盘中最高价报17.05元。截至公告日，项目累计投入研发费用约800万元人民币。上海医药集团股份有限公司决定终止注射用丹酚酸A的临床试验及后续开发。该项目为中药第1类创新药，拟用于冠心病心绞痛，2016年6月获准开展临床试验，现处II期阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0184","02607","BK0187","BK0175","BK0183","BK0188","BK0097","BK1197","BK0012","601607","BK0099","BK0196","BK0028","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653136038","title":"上海医药（601607）披露参与设立上海上实生物医药产业私募基金暨关联交易进展，7月24日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653136038","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653136038?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:16","pubTimestamp":1784902598,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，上海医药报收于16.38元，较前一交易日下跌1.27%，最新总市值为607.43亿元。该股当日开盘16.62元，最高16.69元，最低16.34元，成交额达1.47亿元，换手率为0.32%。近日，上海医药集团股份有限公司发布《关于参与设立上海上实生物医药产业私募基金暨关联/连交易的进展公告》。2026年7月24日，公司已签署《上海上实生物医药产业私募基金合伙企业有限合伙协议》。本次交易构成关联交易。除上述进展外，其他内容与2026年7月18日公告一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400041945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK1197","BK0099","BK0097","BK0184","399441","161726","BK0183","BK0175","BK0028","BK0012","BK0188","02607","BK0209","BK0187","601607","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196223003","title":"上海医药（02607）发布系列公告：终止丹酚酸A临床试验并回应年报问询，披露财务与商誉最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1196223003","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196223003?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:46","pubTimestamp":1784893576,"startTime":"0","endTime":"0","summary":"2026年7月25日，上海医药集团股份有限公司在港交所及上交所同步披露多份公告，涉及研发项目调整、2025年年报问询回复、货币资金与负债结构、财务公司股权收购及商誉减值等事项。上海医药董事会称，为更聚焦优势研发项目，公司决定终止注射用丹酚酸AⅡ期临床试验及后续开发，累计研发投入约3,743万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653081246","title":"上海医药(02607)：决定终止注射用丹酚酸A的临床试验及后续开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2653081246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653081246?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:44","pubTimestamp":1784893480,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，为合理配置研发资源、聚焦优势研发项目，公司基于对研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止注射用丹酚酸A的临床试验及后续开发。注射用丹酚酸A是中药1.2类创新药，拟用于冠心病心绞痛。2016年6月，该项目获国家药品监督管理局批准开展临床试验，现处于临床试验II期阶段。截至目前，该项目累计研发投入共计约人民币3743万元。为合理配置研发资源、聚焦优势研发项目，公司基于对该研发项目未来市场价值、业务协同以及后续开发投入等因素的综合评估，决定终止该研发项目的临床试验及后续开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","IBBQ","BK0012","MDTX","BK0099","BK0188","BK0020","BK0184","BK0196","BK0209","BK0097","BK0028","BK1197","02607","IBBJ","BK0187","601607","BK0183","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187558222","title":"上海医药签署合伙协议推进参与设立上海生物医药二期基金","url":"https://stock-news.laohu8.com/highlight/detail?id=1187558222","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187558222?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:41","pubTimestamp":1784893302,"startTime":"0","endTime":"0","summary":"上海医药（02607）7月25日公告称，公司已于2026年7月24日按照此前披露的主要条款签署合伙协议，正式推进参与设立上海生物医药二期基金。  \n   \n公司此前曾于2026年7月18日发布公告披露拟参与设立上述基金。本次签署合伙协议标志着相关事项取得最新进展。除已披露内容外，原公告中的其他信息保持不变。  \n   \n公告显示，上海医药董事会主席杨秋华代表董事会发布本次公告。公司董事会成员组成亦与此前保持一致，包括4名执行董事、1名非执行董事、1名职工代表董事及4名独立非执行董事。  \n   \n上海医药表示，将根据后续进展及时履行信息披露义务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":-0.0183},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0104},{"period":"6month","weight":0.0344},{"period":"1year","weight":-0.0031},{"period":"ytd","weight":0.0735}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":0.0865},{"period":"3month","weight":-0.0327},{"period":"6month","weight":-0.0388},{"period":"1year","weight":0.0249},{"period":"ytd","weight":-0.0039}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海医药集团股份有限公司是一家主要从事医药分销业务的中国公司。该公司主要经营四个业务分部。工业分部主要从事药品及保健品的研发、生产和销售。分销分部主要从事向医药制造商及配药商提供分销、仓储和其他增值医药供应链解决方案及相关服务。零售分部主要从事经营及加盟零售药店网络。其他分部主要从事其他业务。该公司主要在国内市场经营其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.005822},{"month":2,"riseRate":0.533333,"avgChangeRate":0.014993},{"month":3,"riseRate":0.533333,"avgChangeRate":0.00953},{"month":4,"riseRate":0.533333,"avgChangeRate":0.000651},{"month":5,"riseRate":0.466667,"avgChangeRate":-0.003721},{"month":6,"riseRate":0.5,"avgChangeRate":-0.010249},{"month":7,"riseRate":0.375,"avgChangeRate":-0.010293},{"month":8,"riseRate":0.375,"avgChangeRate":0.009685},{"month":9,"riseRate":0.333333,"avgChangeRate":0.013112},{"month":10,"riseRate":0.266667,"avgChangeRate":-0.02141},{"month":11,"riseRate":0.466667,"avgChangeRate":0.029699},{"month":12,"riseRate":0.533333,"avgChangeRate":-0.012572}],"exchange":"SEHK","name":"上海医药","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,02607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}